Tectonic Therapeutics Announces Positive Phase 1a Results For TX45 In Treating Group 2 PH-HFpEF
20/9 05:14
(RTTNews) - Tectonic Therapeutics Inc. (TECX) announced favorable Phase 1a topline data for its lead asset, TX45, a long-acting, potentially best-in-class relaxin developed for the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-H...